India · Paediatric mg/kg & Adult · Skin · Bone · Dental · MRSA · Anaerobic · Dalacin C · Clindac
| Patient | Indication | Dose | Frequency | Duration |
|---|---|---|---|---|
| Child | Mild skin / soft tissue | 8–12 mg/kg/day (max 1.8g/day) | Every 8h (TDS) | 5–7 days |
| Child | Moderate-severe / bone | 16–20 mg/kg/day | Every 6–8h | 4–6 weeks (bone) |
| Child | Severe / MRSA | 25–40 mg/kg/day (max 40 mg/kg/day) | Every 6h (QDS) | As directed |
| Child | IE prophylaxis (single) | 20 mg/kg (max 600 mg) | Single dose 30–60 min pre-procedure | Single dose |
| Adult | Mild skin / dental | 150–300 mg | Every 6h (QDS) | 5–7 days |
| Adult | Moderate-severe / MRSA | 300–450 mg | Every 6h (QDS) | 7–14 days |
| Adult | Osteomyelitis (IV→oral) | 600 mg IV → 300–450 mg oral | Every 6–8h | 4–6 weeks total |
| Adult | Pelvic / intra-abdominal | 600–900 mg IV | Every 8h (TDS) | 7–14 days |
| Adult | IE prophylaxis (single) | 600 mg | Single dose pre-procedure | Single dose |
Clindamycin is a lincosamide antibiotic with excellent activity against Gram-positive cocci and anaerobic bacteria. It is particularly valued in Indian clinical practice for three reasons: its exceptional bone and joint penetration (making it the drug of choice for paediatric osteomyelitis and septic arthritis), its activity against community-acquired MRSA (CA-MRSA), and its effectiveness against the anaerobic organisms implicated in dental, pelvic, and intra-abdominal infections. It is available as Dalacin C and Clindac in India in capsule and IV formulations.
In paediatric practice, clindamycin is one of the most important antibiotics for bone and joint infections. Unlike many other antibiotics, it achieves bone concentrations of 35–40% of serum levels — effectively treating osteomyelitis. The oral bioavailability of clindamycin is approximately 90%, which enables IV-to-oral step-down earlier than most other bone infection antibiotics, reducing hospital stay.
The paediatric clindamycin dose is weight-based and severity-stratified. For mild skin infections: 8–12 mg/kg/day in 3 divided doses. For moderate infections (including most community MRSA): 16–20 mg/kg/day in 3–4 divided doses. For severe infections, including osteomyelitis and bacteraemia: 25–40 mg/kg/day in 4 divided doses. The maximum paediatric daily dose is 40 mg/kg/day (max absolute 1.8g/day in mild infections, up to 2.7g/day for severe). No renal dose adjustment is needed in children, as hepatic metabolism predominates.
Community-acquired MRSA (CA-MRSA) is an increasingly recognised pathogen in Indian skin and soft tissue infections, paediatric bone infections, and necrotising fasciitis. Unlike hospital-acquired MRSA (HA-MRSA), CA-MRSA strains in India retain susceptibility to clindamycin in a significant proportion of isolates. However, inducible clindamycin resistance — detected by the D-zone test (double-disc diffusion with erythromycin) — is common in Indian MRSA strains. A D-zone positive result means clindamycin resistance can develop during therapy and the drug should not be used, despite appearing sensitive on routine disc diffusion. Always request D-zone testing when treating MRSA with clindamycin.
Clindamycin is the preferred antibiotic for odontogenic infections in penicillin-allergic patients, due to its excellent coverage of oral anaerobes (Bacteroides, Peptostreptococcus, Fusobacterium) and streptococci. Standard adult dose: 150–300 mg every 6 hours for 5–7 days. For infective endocarditis prophylaxis in penicillin-allergic patients (AHA/BNF guidelines): 600 mg as a single oral dose 30–60 minutes before dental procedures.
Clindamycin is one of the antibiotics most frequently implicated in Clostridioides (formerly Clostridium) difficile-associated diarrhoea (CDAD) — due to disruption of colonic anaerobic flora. In Indian hospitals, where C. difficile testing is underutilised, any diarrhoea developing during or after clindamycin use should be taken seriously. Stop clindamycin, send stool for C. difficile toxin assay, and treat with oral metronidazole (mild-moderate) or vancomycin (severe) if confirmed.